| AcSDKP | N-acetyl-seryl-lysyl-proline |
| ACE | Angiotensin-converting enzyme |
| ACE2 | Angiotensin-converting enzyme 2 |
| AMPK | AMP-activated protein kinase |
| ARDS | Acute respiratory distress syndrome |
| ALI | Acute lung injury |
| CKD | Chronic kidney disease |
| COVID-19 | Coronavirus disease 2019 |
| CXCL1 | Chemokine ligand 1 |
| DPP-4 | Dipeptidyl transferase-4 |
| DKD | Diabetic kidney disease |
| DM | Diabetes mellitus |
| DN | Diabetic nephropathy |
| ECM | Extracellular matrix |
| EMT | Epithelial-to-mesenchymal transition |
| EndMT | Endothelial-to-mesenchymal transition |
| ESRD | End-stage renal disease |
| FGFR1 | Fibroblast growth factor receptor 1 |
| GLP-1 | Glucagon-like peptide-1 |
| GR | Glucocorticoid receptor |
| KRT | Kidney replacement therapy |
| LncRNA | Long noncoding RNAs |
| LNA | Locked nucleic acid |
| MALAT1 | Metastasis-associated lung adenocarcinoma transcript 1 |
| MiRNA | MicroRNA |
| MMT | Macrophage-to-mesenchymal-transition |
| NEAT1 | Nuclear enriched abundant Transcript-1 |
| NLRP3 | NOD-, LRR- and pyrin domain-containing protein 3 |
| PDGF | Platelet-derived growth factor |
| RAAS | Renin angiotensin system |
| RBD | Receptor binding domain |
| RCT | Random clinical trials |
| SIRT3 | Sirtuin 3 |
| SARS-CoV-2 | Severe acute respiratory syndrome coronavirus 2 |
| TMPRSS2 | Transmembrane protease serine 2 receptors |
| TGFβ1 | Transforming growth factor β1 |
| TNF α | Tumor necrosis factor α |
| VEGF | Vascular endothelial growth factor |